Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
Journal of Alzheimer’s Disease · 25.07.2023 · 94 (s1) · S399-S428
DOI: 10.3233/jad-220682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 06.09.2022. Verfasst von Padmashri Naren und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Parkinson’s disease (PD) is the second most common neurodegenerative illness majorly affecting the population between the ages of 55 to 65 years. Progressive dopaminergic neuronal loss and the collective assemblage of misfolded alpha-synuclein in the substantia nigra, remain notable neuro-pathological hallmarks of the disease. Multitudes of mechanistic pathways have been proposed in attempts to unravel the pathogenesis of PD but still, it remains elusive. The convergence of PD pathology is found in organelle dysfunction where mitochondria remain a major contributor. Mitochondrial processes like bioenergetics, mitochondrial dynamics, and mitophagy are under strict regulation by the mitochondrial genome and nuclear genome. These processes aggravate neurodegenerative activities upon alteration through neuroinflammation, oxidative damage, apoptosis, and proteostatic stress. Therefore, the mitochondria have grabbed a central position in the patho-mechanistic exploration of neurodegenerative diseases like PD. The management of PD remains a challenge to physicians to date, due to the variable therapeutic response of patients and the limitation of conventional chemical agents which only offer symptomatic relief with minimal to no disease-modifying effect. This review describes the patho-mechanistic pathways involved in PD not only limited to protein dyshomeostasis and oxidative stress, but explicit attention has been drawn to exploring mechanisms like organelle dysfunction, primarily mitochondria and mitochondrial genome influence, while delineating the newer exploratory targets such as GBA1, GLP, LRRK2, and miRNAs and therapeutic agents targeting them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India.
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Hyderabad, Telangana, India.
- Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.) Varanasi (U.P.), India.
Zitieren
APA
Naren, P., Cholkar, A., Kamble, S., Khan, S. S., Srivastava, S., Madan, J., Mehra, N., Tiwari, V., Singh, S. B., & Khatri, D. K. (2023). Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay. Journal of Alzheimer’s Disease, 94(s1), S399-S428. https://doi.org/10.3233/jad-220682
Vancouver
Naren P, Cholkar A, Kamble S, Khan SS, Srivastava S, Madan J, et al. Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay. Journal of Alzheimer’s Disease. 2023;94(s1):S399-S428. doi:10.3233/jad-220682
BibTeX
@article{Naren2023,
author = {Naren, Padmashri and Cholkar, Anjali and Kamble, Suchita and Khan, Sabiya Samim and Srivastava, Saurabh and Madan, Jitender and Mehra, Neelesh and Tiwari, Vinod and Singh, Shashi Bala and Khatri, Dharmendra Kumar},
title = {Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay},
journal = {Journal of Alzheimer’s Disease},
year = {2023},
volume = {94},
number = {s1},
pages = {S399--S428},
doi = {10.3233/jad-220682}
}
EUVIMED